SentinelOne Named a Leader in the 2021 Gartner Magic Quadrant for Endpoint Protection Platforms
10.5.2021 19:12:00 EEST | Business Wire | Press release
SentinelOne, the autonomous cybersecurity platform company, today announced it has been positioned by Gartner as a Leader in the 2021 Magic Quadrant for Endpoint Protection Platforms1. SentinelOne believes the placement is a testament to the company’s innovative Singularity XDR platform and scaled go-to-market execution in record time. We believe this accomplishment signifies unrivaled product-market fit, innovation, and superb customer experience across a diverse set of customer profiles.
“Modern society is digital, and every place where data resides is vulnerable. Human-powered products simply cannot keep up with the exponentially growing threat landscape. Our AI-powered technology is the automated solution to modern day cyberattacks,” said Tomer Weingarten, CEO and Co-founder, SentinelOne. “We believe being named a Leader in the Gartner Magic Quadrant validates our approach and aligns with the market traction we’re experiencing. I am proud our team continues to deliver innovation, scale, and growth – all while keeping our customers protected.”
“SentinelOne is experiencing hypergrowth new logo adoption as well as module expansion from our existing customer base,” said Nicholas Warner, COO, SentinelOne. “We continue to outperform next-gen and legacy EPP vendors around the globe in comparative evaluations, demonstrating our ability to address cybersecurity at the pace and scale needed by modern businesses of all sizes to defeat attacks at machine speed.”
With excellent scores across EDR, EPP, and MDR in Gartner Peer Reviews, SentinelOne continues to deliver best-in-class customer satisfaction to its rapidly expanding global customer base of leading enterprises. In addition to being named a Leader in this year’s Magic Quadrant, SentinelOne received the highest overall rating and most verified reviews for the overall rating category in the 2020 Gartner Peer Insights ‘Voice of the Customer’: Endpoint Detection and Response Solutions report, and was recognized as a November 2019 Gartner Peer Insights Customers’ Choice for Endpoint Protection Platforms.
Gartner Peer Insights documents customer experience through verified ratings and peer reviews from enterprise IT professionals. As of April 23, 2021, SentinelOne reviews include the following:
“SentinelOne is a pioneering solution in endpoint protection with a rapid development lifecycle, best-of-breed platform support, and an unrivaled API.” - Information Security Manager, Manufacturing [read full review]
“SentinelOne has become a main piece of our security portfolio. It was deployed to the majority of workstations and servers in our environment nearly overnight.” - Sr. Cybersecurity Analyst, Miscellaneous [read full review]
“We looked at Cylance, Crowdstrike, Microsoft ATP Defender, Carbon Black and SentinelOne. Overall, S1 is an absolute game changer. These guys are disrupting traditional cyber security in a big way and will leave every CISO and their organization with little doubt about the right choice of EDR product.” - Senior Director, Cyber Security, Retail [read full review]
“We couldn't be happier with SentinelOne! We did our own lab comparison of 11 products. SentinelOne came out on top easily!" [read full review]
“SentinelOne has been critical in protecting our business. This platform provides not only next-gen AV, but also EDR. We actually made the decision to not renew our existing EDR platform because of SentinelOne's advanced EDR features.” - VP -- Detection and Response, Finance [read full review]
- To register for our upcoming webinar on Wednesday, May 19th at 10:00 AM PDT, please visit: LINK
- Download a complimentary copy of the 2021 Gartner Magic Quadrant for Endpoint Protection platforms by visiting: LINK
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights reviews constitute the subjective opinions of individual end users based on their own experiences and do not represent the views of Gartner or its affiliates.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
About SentinelOne
SentinelOne is the leading cybersecurity solution encompassing AI-powered prevention, detection, response and hunting across endpoints, containers, cloud workloads, and IoT devices in a single autonomous platform. With SentinelOne, organizations gain transparency into everything happening across the network at machine speed – to defeat attacks, at every stage of the threat lifecycle. To learn more visit www.sentinelone.com or follow us at @SentinelOne, on LinkedIn or Facebook.
1 Gartner, Magic Quadrant for Endpoint Protection Platforms, Paul Webber, Peter Firstbrook, Rob Smith, Mark Harris, Prateek Bhajanka, 5 May 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005705/en/
Contact information
Maryellen Sartori
fama PR for SentinelOne
P: 617-986-5035
E: S1@famapr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom